Analyzing...
Loading company...
Panacea Biotec Ltd. is a biotechnology company, which is engaged in the business of research, development, manufacture, and marketing of vaccines and pharmaceutical formulations. The company is headquartered in New Delhi, Delhi. The firm manufactures a range of paediatric vaccines, including hexavalent vaccine, EasySixTM; pentavalent vaccine, Easyfive- TT and bivalent oral polio vaccine in India and market the same in India, as well as in international markets. The Company’s products include EasySix, Easyfive-TT, Easyfour-TT, EasyFourPol and Bi-OPV. Its pipeline candidates include BPBC, Hepatitis A, Covid-19 VoC mAb, NuVac-23, NuCoVac-11, Td and DengiAll. The firm is in the process of initiating phase III clinical trials for NucoVac-11, DengiAll and Td vaccines. Its operations are spread across different geographies in India. The firm has two manufacturing facilities located in Lalru, Punjab and Baddi, Himachal Pradesh, and two research and development (R&D) centers in Lalru, Punjab and New Delhi.
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹640 Cr revenue.
COGS 43.8%, employees 28.3%.
| KPI | Company | Sector Median |
|---|---|---|
| ROE | -0.6%▼ | 10.3% |
| ROCE | -0.1%▼ | 13.7% |
| Net Margin | -0.8%▼ | 7.6% |
| EBITDA Margin | 4.8%▼ | 15.4% |
| Debt To Equity | 0.03x▼ | 0.15x |
| Rev Growth 3yr | 8.7%▼ | 10.0% |
| EPS Growth 3yr | -45.7%▼ | 16.0% |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Revenue | ₹640 Cr +14.4% | ₹559 Cr -0.0% | ₹559 Cr +21.6% | ₹460 Cr -30.4% | ₹661 Cr +5.8% | ₹625 Cr +14.8% | ₹544 Cr |
| Other Income | ₹17 Cr -18.2% | ₹21 Cr -19.9% | ₹26 Cr -50.1% | ₹52 Cr +370.9% | ₹11 Cr +9.9% | ₹10 Cr -66.4% | ₹30 Cr |
| Total Income | ₹657 Cr +13.3% | ₹580 Cr -0.9% | ₹585 Cr +14.3% | ₹512 Cr -23.9% | ₹672 Cr +5.9% | ₹635 Cr +10.6% | ₹574 Cr |
| COGS | ₹280 Cr +40.6% | ₹200 Cr -13.3% | ₹230 Cr -8.9% | ₹253 Cr -3.6% | ₹262 Cr +28.1% | ₹205 Cr +30.5% | ₹157 Cr |
| ₹684 Cr +9.6% | ₹624 Cr +0.7% | ₹620 Cr +3.0% | ₹601 Cr -33.1% | ₹900 Cr +15.5% | ₹779 Cr +6.7% | ₹730 Cr | |
| Profit Before Tax | (₹7 Cr) +7.3% | (₹8 Cr) ↓ Decline | ₹1 Cr -88.4% | ₹13 Cr -99.1% | ₹1,449 Cr ↑ Recovery | (₹144 Cr) +15.9% | (₹172 Cr) |
| Exceptional Items | ₹20 Cr -45.8% | ₹36 Cr -0.1% | ₹36 Cr -64.9% | ₹103 Cr -93.9% | ₹1,676 Cr | ₹0.00 Cr +100.0% | (₹15 Cr) |
| (₹0.21 Cr) ↓ Decline | ₹0.77 Cr -74.2% | ₹3 Cr -93.6% | ₹47 Cr -87.4% | ₹371 Cr | ₹2 Cr -88.2% | ₹17 Cr | |
| Net Profit | (₹7 Cr) +17.9% | (₹9 Cr) -481.3% | (₹2 Cr) +95.6% | (₹34 Cr) ↓ Decline | ₹1,078 Cr ↑ Recovery | (₹146 Cr) +22.2% | (₹188 Cr) |
| Profit (Owners) | (₹5 Cr) +35.8% | (₹8 Cr) -615.4% | (₹1 Cr) +96.5% | (₹34 Cr) ↓ Decline | ₹1,078 Cr ↑ Recovery | (₹148 Cr) +24.0% | (₹194 Cr) |
| Minority Interest | (₹2 Cr) -411.4% | (₹0.35 Cr) -6.1% | (₹0.33 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| Other Comprehensive Income | ₹5 Cr +388.3% | ₹1 Cr ↑ Recovery | (₹0.39 Cr) ↓ Decline | ₹0.28 Cr ↑ Recovery | (₹0.40 Cr) ↓ Decline | ₹0.82 Cr -70.2% | ₹3 Cr |
| EPS | (₹0.88) | (₹1.37) | (₹0.19) | (₹5.51) | ₹175.98 | (₹24.11) | (₹31.72) |
| Diluted Shares | ₹6 Cr | ₹6 Cr | ₹6 Cr | ₹6 Cr | ₹6 Cr | ₹6 Cr | ₹6 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
No earnings call transcripts available.
Panacea Biotec Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Panacea Biotec Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Panacea Biotec Limited has informed the Exchange regarding 'Details of Shares dematerialized during June 2026'.
Panacea Biotec Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Panacea Biotec Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Dr. Rajesh Jain Karta of Rajesh Jain (HUF) has submitted to the Exchange a copy of Disclosures under Regulation 10(6)-Report to stock Exchange in respect of any acquisition made in reliance upon exemp...
Panacea Biotec Limited has informed the Exchange about Copy of Newspaper Publication
Panacea Biotec Limited has informed the Exchange about Copy of Newspaper Publication
Panacea Biotec Limited has informed the Exchange about change in directors in the Company's material wholly owned subsidiary, Panacea Biotec Pharma Limited
Panacea Biotec Limited has informed the Exchange regarding 'Details of Shares dematerialized during April 2026 under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018'.
Panacea Biotec Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Panacea Biotec Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Panacea Biotec Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Panacea Biotec Limited has informed the Exchange regarding 'Details of Shares dematerialized during February 2026'.
Panacea Biotec Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
No dividend history available for this company.